ResearchMoz

Ritonavir - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Publisher Name » GenericsWeb
Published Date » 2011-12-01
No. Of Pages » N/A
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Ritonavir
Ritonavir indications: Treatment of HIV infection
Ritonavir innovator: Abbott (Norvir, Kaletra)

Examples of information found in this online report include:
# Includes key patent publications for 44 countries (see list below)
# Contains SPC protection for every EU state plus patent term extensions in other countries
# Data exclusivity calculated on a country by country basis
# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
# DMF & Paragraph IV filings
# Litigation alerts
# Marketing authorisation holders in selected territories
# Patent risk analysis via graphical display of data from patent filings
# Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA. (also available with 44 country coverage):

Pipeline Selector 44 Country Coverage:

Country Region Extensions
Australia Asia-Pacific S70
Canada Americas N/A
USA Americas S156
Germany Western Europe SPC
Great Britain Western Europe SPCS
France Western Europe NAT/SPC
Spain Western Europe SPC
South Africa Africa N/A
China Asia-Pacific N/A
Japan Asia-Pacific S67
New Zealand Asia-Pacific N/A
Bosnia & Herzegovina Balkan N/A
Bulgaria Balkan SPC
Croatia Balkan N/A
Romania Balkan SPC
Slovenia Balkan NAT/SPC
Estonia Baltic NAT/SPC
Lithuania Baltic NAT/SPC
Latvia Baltic NAT/SPC
Czech Republic Central Europe NAT/SPC
Hungary Central Europe SPC
Poland Central Europe SPC
Slovakia Central Europe NAT/SPC
Serbia & Montenegro Central Europe N/A
Cyprus Mediterranean NAT/SPC
Greece Mediterranean SPC
Israel Mediterranean NAT
Malta Mediterranean SPC
Turkey Mediterranean N/A
Denmark Scandinavia SPC
Finland Scandinavia SPC
Iceland Scandinavia SPC
Norway Scandinavia SPC
Sweden Scandinavia SPC
Brazil South America N/A
Mexico South America N/A
Austria Western Europe SPC
Belgium Western Europe SPC
Switzerland Western Europe NAT/SPC
Ireland Western Europe SPC
Italy Western Europe NAT/SPC
Luxembourg Western Europe SPC
The Netherlands Western Europe SPC
Portugal Western Europe SPC


Other key information contained in the report:

# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**.
# News articles
# Litigation alerts
# Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
# US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
# Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
# 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.


*Key Patent Indicator
The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report).

**General Drug Information
Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.

***Patent Risk Analysis
The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.


Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. 

# Includes key patent publications for 44 countries 
# Contains SPC protection for every EU state plus patent term extensions in other countries
# Data exclusivity calculated on a country by country basis
# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
# DMF & Paragraph IV filings
# Litigation alerts
# Marketing authorisation holders in selected territories
# Patent risk analysis via graphical display of data from patent filings
# Hyper-linking to crucial patent documents and national registries enabling data verification

List of Tables

NA

List of Figures

NA

Upcoming Reports:

Neurometabolic Disorders Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Some of the factors driving neurometabolic disorders market are rising incidences of neurometabolic disorders and growing ageing population. Launch of new drugs coupled with the rising awareness among patients and physicians are expected to increase revenues for the neurometabolic disorders industry in the coming years.  Government agencies and private companies are taking extra measures to increase awareness among patients and physicians regarding diseases and their available treatment options. Enzyme replacement therapy (ERT) is currently the available therapeutic...
HPV Testing Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The cancer diagnostics market is on the verge of sudden increase due to the technological breakthroughs in tumor diagnosis and unlocking of mysteries of genetics. The HPV (Human Papilloma Virus) testing market is expected to witness a promising growth in the next few years due to rising incidences of cancerous tumors and the growing ageing population.  Predictable technological breakthroughs are creating a number of opportunities for genetic study, detecting specific tumors, and monitoring biological responses to cancer therapy. Rise in the elderly population will further...
Animal Therapeutics and Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
The similarities in the structure and functioning of body parts in humans and in animals increases the size of the animal therapeutics and diagnostics market. The rising number of pet adoptions across the globe, rising incidences of chronic diseases such as bovine spongiform encephalopathy, rising global meat consumption, and the rising incidences of pet obesity, especially in developed countries such as the U.S., are some of the growth drivers for the market.  The global animal therapeutics and diagnostics market is segmented on the basis of products into...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...